Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 131, Issue 2, 2006, Pages 352-356

  Carrier, M ^a   Menasche P ^b   Levy, J H ^b   Newman, M F ^b   Taylor, K M ^b   Haverich, A ^b   Chen, J C ^b   Shernan, S K ^b   Van De Werf, F ^b   Van Der Laan, M ^b   Todaro, T G ^b   Adams, P X ^b   Verrier, E D ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; PEXELIZUMAB;

ADULT; AGED; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY;

AGED; ANTIBODIES, MONOCLONAL; AORTIC VALVE; CARDIOPULMONARY BYPASS; COMPLEMENT INACTIVATING AGENTS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS;

EID: 31044450701     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2005.10.011     Document Type: Article

References (8)

1. S.K. Shernan, J.C. Fitch, N.A. Nussmeier, J.C. Chen, S.A. Rollins, C.F. Mojcik Impact of Pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass Ann Thorac Surg 77 2004 92 95
2. C.S. Rinder, H.M. Rinder, B.R. Smith, J.C. Fitch, M.J. Smith, J.B. Tracey Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J Clin Invest 96 1995 1564 1572
3. A.P. Vakeva, A. Agah, S.A. Rollins, L.A. Matis, L. Li, G.L. Stahl Myocardial infarction and apoptosis after myocardial ischemia and reperfusion Circulation 97 1998 2259 2267
4. J.C. Fitch, S. Rollins, L. Matis, B. Alford, S. Aranki, C.D. Collard Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass Circulation 100 1999 2499 2506
5. E.D. Verrier, S.K. Shernan, K.M. Taylor, F. Van de Werf, M.F. Newman, J.C. Chen Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass JAMA 291 2004 2319 2327
6. T.C. Thomas, S.A. Rollins, R.P. Rother, M.A. Giannoni, S.L. Hartman, E.A. Elliott Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv Mol Immunol. 33 1996 1389 1401
7. X.Y. Jin, D.G. Gibson, J.R. Pepper Early changes in regional and global left ventricular function after aortic valve replacement Circulation 92 suppl II 1995 II155 II162
8. K. Klatte, B.R. Chaitman, P. Theroux, J.A. Gavard, K. Stocke, S. Boyce Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release J Am Coll Cardiol 38 2001 1070 1077